Connecting science with real life by driving policy evolution at the highest political level, the Summit:
- Debated leading-edge ideas on outcomes research, health economics and organisation of cancer care delivery
- Determined consensus resolutions for improving health systems
- Decided on an action plan for the way forward to ensure ideas translate into policies that will impact daily clinical practice
The ECCO 2018 European Cancer Summit was much more than a coming-together of leaders in the cancer policy field. By forming high level resolutions on the organisation of cancer care, the Summit represented an important ‘working together’ of diverse stakeholder interests, creating and expressing new consensus on the change required within European health systems to deliver the best care to cancer patients.
Improving the measurement of quality cancer care, addressing financial discrimination endured by cancer survivors and better integrating primary care to improve cancer care were the three major themes of the ECCO 2018 European Cancer Summit resolutions.
The draft resolutions were formed via meetings of the European Cancer Organisation's Oncopolicy Committee and Patient Advisory Committee in April 2018, followed by a wider process of virtual consultation with the European Cancer Organisation's member societies and patient advocates thereafter. The final resolutions were passed at the Summit and provide a powerful charter, and roadmap, for organisational improvement in all European health systems.
This resolution builds on the work of the European Cancer Organisation in respect to the Essential Requirements for Quality Cancer Care, as well as initiatives of member societies of the European Cancer Organisation such as the Accreditation and Designation Programme of the Organisation of European Cancer Institutes (OECI).
* For the purposes of this resolution, “financial services” are understood to refer to services and products provided to consumers and businesses by financial institutions such as banks, insurance companies, brokerage firms, consumer finance companies, and investment companies (Source: investorwords.com).
** For the purpose of this resolution, “active treatment” does not include maintenance treatment with hormonotherapy, immunotherapy, targeted therapy or other therapies based on sound and increasing evidence.
** This amendment was proposed and agreed by delegates at the Summit